Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Raúl Sánchez-Hernández *Departamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0009-0006-3814-8520
Miguel Benítez-Angeles *Departamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0009-0004-2387-3936
Irina A TalyzinaDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032.
Itzel LlorenteDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0009-0003-2790-988X
Mariela González-AvendañoDepartment of Bioinformatics, Center for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Talca 3460000, Chile.
Félix SierraDepartamento de Neuropatología Molecular, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Angélica Méndez-ReséndizDepartamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.
Francisco MercadoLaboratorio de Fisiología Celular, Dirección de Investigaciones en Neurociencias, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 14370, Mexico.ORCID 0000-0001-6060-2618
Ariela Vergara-JaqueDepartment of Bioinformatics, Center for Bioinformatics, Simulation and Modeling, Faculty of Engineering, Universidad de Talca, Talca 3460000, Chile.
Alexander I SobolevskyDepartment of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032.ORCID 0000-0001-5181-8644
León D IslasDepartamento de Fisiología, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-7461-5214
Tamara RosenbaumDepartamento de Neurociencia Cognitiva, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico.ORCID 0000-0002-4791-3195
Funding
Pacific Northwest Center for Cryo-EM: Equipment SupplementR24GM154185 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI James E Evans, CLAUDIA SUSANA LOPEZ · 2024 to 2026
$21.5M
Structure and function of Transient Receptor Potential ChannelsR01CA206573 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alexander Sobolevsky · 2017 to 2026
$3.8M
Single-Particle Cryo-EM Characterization of AMPA Receptor Functional StatesR01NS107253 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alexander Sobolevsky · 2018 to 2026
$3.5M
Structural and functional principles of activation and regulation of the transient receptor potential channel TRPV3.R01AR078814 · NIAMS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alexander Sobolevsky · 2022 to 2026
$2.8M
Structure and Function of Ionotropic Glutamate ReceptorsR37NS083660 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Alexander Sobolevsky · 2024 to 2026
$1.7M
Agencia Nacional de Investigación y Desarrollo Doctoral Fellowship 21212329ANID | Fondo Nacional de Desarrollo Científico y Tecnológico (FONDECYT) 1220110Consejo Nacional de Humanidades, Ciencias y Tecnologías (Conahcyt) CBF23-24-46Consejo Nacional de Humanidades, Ciencias y Tecnologías (Conahcyt) CF-2023-G-513HHS | National Institutes of Health (NIH) R01AR078814HHS | National Institutes of Health (NIH) R01CA206573HHS | National Institutes of Health (NIH) R01NS107253HHS | National Institutes of Health (NIH) R24GM154185HHS | National Institutes of Health (NIH) R37NS083660NCI NIH HHS R01 CA206573NIAMS NIH HHS R01 AR078814NIGMS NIH HHS R24 GM154185NINDS NIH HHS R01 NS107253NINDS NIH HHS R37 NS083660UNAM | Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (DGAPA) IN200423UNAM | Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México (DGAPA) IN201824
6 · The paper itself
Abstract
The Transient Receptor Potential Vanilloid 1 (TRPV1) ion channel is expressed in primary nociceptive afferents, which participate in processes such as pain and inflammation. Considerable efforts have been directed toward finding inhibitors of TRPV1 and understanding the molecular details of their interactions with this channel. α-humulene (AH) is a sesquiterpene derived from plants such as hops and other members of Cannabaceae family, with a long history of popular use as an analgesic and anti-inflammatory. Using a combination of behavioral assays, electrophysiology, site-directed mutagenesis, cryo-EM, and molecular dynamics simulations, we show that AH inhibits TRPV1-related pain responses and currents by interacting with a region composed of the S2, S2-S3 linker, and S3 transmembrane segments and stabilizing the closed conformation of the channel. The interaction of ligands in this region of the TRPV1 channel has not been previously described and the results of the present study highlight that it may constitute part of a negative regulatory region. These findings allow us to understand the molecular basis by which substances such as some sesquiterpenes, abundantly found in medicinal plants used by humans for hundreds of years, reduce pain. Pain management can include the use of opioids, which results in hepatic and renal damage and possible addiction. Our study offers insight into a poorly understood group of compounds that could be used as scaffold to produce novel nonopioid analgesic therapies and clarifies the molecular mechanisms that underlie the effects of these analgesic molecules.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Structural basis of the inhibition of TRPV1 by analgesic sesquiterpenes. · full record | OpenQuestion